Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 184,733 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NOT program Clear all
Completed Early Phase 1 Interventional

TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia

NCT04518345
View directory record Official record
Conditions
Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Interventions
Azacitidine, Dubermatinib
Drug
Lead sponsor
Uma Borate
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 23, 2026, 4:55 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)

NCT02634645
View directory record Official record
Conditions
Barrett's Esophagus, Esophageal Cancer
Interventions
Endoscopic eradication therapies (EET), Esophagectomy, Chemotherapy, Radiation
Procedure · Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 23, 2026, 4:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Scanadu Consumer Health Outcomes (SCOUT) Study

NCT02134145
View directory record Official record
Conditions
Disorder Characterized by Fever
Interventions
Not listed
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
19 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 23, 2026, 4:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Using Ultrasound to Study Respiratory Muscle Function in Critically Ill Patients

NCT03139695
View directory record Official record
Conditions
Injury of Diaphragm, Mechanical Ventilation Complication, Critical Illness
Interventions
Ultrasound
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 23, 2026, 4:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers

NCT00777595
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
CHF 4226 pMDI, Placebo, Moxifloxacin
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2009 · Synced Oct 23, 2026, 4:55 PM EDT
Completed Not applicable Interventional Results available

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

NCT01005745
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Surgery, Administration of Lymphodepletion, Adoptive Cell Transfer, High Dose IL-2
Procedure · Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 23, 2026, 4:55 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effect of Exercise and Education After Pneumonia

NCT01744145
View directory record Official record
Conditions
Pneumonia
Interventions
Interventional 40-60, Interventional 60 and above
Other
Lead sponsor
Winthrop University Hospital
Other
Eligibility
40 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 23, 2026, 4:55 PM EDT
Completed Early Phase 1 Interventional

A Feasibility Trial of OCM Supplements for the Treatment of NAFLD

NCT05720702
View directory record Official record
Conditions
NAFLD
Interventions
homocysteine (Hcy) lowering supplements
Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 23, 2026, 4:55 PM EDT
Completed Phase 3 Interventional

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

NCT05568095
View directory record Official record
Conditions
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Interventions
Domvanalimab, Zimberelimab, Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Nivolumab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
31
States / cities
Los Angeles, California • Orange, California • Santa Monica, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 23, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors

NCT01901172
View directory record Official record
Conditions
Neoplasms
Interventions
RO5503781, posaconazole
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Scottsdale, Arizona • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Oct 23, 2026, 4:55 PM EDT
Recruiting Phase 3 Interventional

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

NCT06064877
View directory record Official record
Conditions
Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Ficlatuzumab, Cetuximab, Placebo
Biological · Other
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
28
States / cities
Gilbert, Arizona • Tucson, Arizona • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 23, 2026, 4:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists

NCT04196777
View directory record Official record
Conditions
Urologic Diseases, Antibacterial Drug Adverse Reaction
Interventions
Audit-and-feedback
Behavioral
Lead sponsor
Iowa City Veterans Affairs Medical Center
Federal
Eligibility
Not listed
Enrollment
525 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Gainesville, Florida • Iowa City, Iowa • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 4:55 PM EDT
Active, not recruiting Phase 2 Interventional

A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

NCT06007677
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
STAR-0215
Drug
Lead sponsor
Astria Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 23, 2026, 4:55 PM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes

NCT00821977
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Vildagliptin, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
141
States / cities
Pell City, Alabama • Gilbert, Arizona • Mesa, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 23, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus

NCT00225277
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
35 Years to 85 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 23, 2026, 4:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

NCT04776239
View directory record Official record
Conditions
Diabetes Mellitus, Ischemic Heart Disease
Interventions
100 million Allogeneic Mesenchymal Human Stem Cells, Placebo
Drug · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 23, 2026, 4:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Feasibility Study of a Percutaneous Mitral Valve Repair System.

NCT00209339
View directory record Official record
Conditions
Mitral Valve Insufficiency, Mitral Valve Regurgitation, Mitral Valve Incompetence, Mitral Regurgitation, Mitral Insufficiency
Interventions
Percutaneous mitral valve repair (MitraClip Implant)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 23, 2026, 4:55 PM EDT
Not listed Not applicable Interventional

Changes in Biochemical Markers of Bone Turnover (Serum CTX and PlNP) After Initiation of a "Drug Holiday" From Bisphosphonates

NCT02575157
View directory record Official record
Conditions
Osteoporosis
Interventions
No intervention
Other
Lead sponsor
National Bone Health Alliance
Other
Eligibility
50 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 23, 2026, 4:55 PM EDT
Completed Phase 4 Interventional Results available

Duloxetine for Menopausal Depression

NCT01117857
View directory record Official record
Conditions
Depression, Menopause, Vasomotor Symptoms
Interventions
Duloxetine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 23, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder

NCT05103657
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
BI 1358894, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
37
States / cities
Little Rock, Arkansas • Glendale, California • Long Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 23, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols

NCT00884312
View directory record Official record
Conditions
Multiple Myeloma, Solid Tumors
Interventions
Carfilzomib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
21
States / cities
Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 23, 2026, 4:55 PM EDT
Recruiting Not applicable Interventional

Reward Sensitivity Digital Intervention for Suicide Risk

NCT07661901
View directory record Official record
Conditions
Suicidal Ideation, Suicidal, Suicidal Thoughts, Digital Health Intervention, Reward Sensitivity, Anhedonia
Interventions
Suicide prevention treatment
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
13 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 23, 2026, 4:55 PM EDT
Completed Not applicable Interventional

Qigong Therapy For Heart Device Patients

NCT00027001
View directory record Official record
Conditions
Depressive Disorder, Cardiac Diseases
Interventions
Aerobic and Resistance Exercises, Qigong
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 23, 2026, 4:55 PM EDT
Recruiting Phase 2 Interventional

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

NCT07321912
View directory record Official record
Conditions
Osteosarcoma, Ewing Sarcoma
Interventions
Eflornithine, Topotecan, Cyclophosphamide, Vincristine, Doxorubicin, Ifosfamide, Etoposide, Cisplatin, Methotrexate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
0 Years to 50 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
3
States / cities
Tampa, Florida • Portland, Oregon • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 4:55 PM EDT